Beyond BCR::ABL1 mutations, genetic alterations have been critically evaluated for their role in conferring Imatinib resistance, especially in cancers like gastrointestinal stromal tumors (GISTs), where mutations in the KIT or PDGFRA genes are prevalent [29]. This evidence concerns the gene PDGFRA and gastrointestinal stromal tumor.